Lead exposure and cardiovascular disease--a systematic review.
Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. · 2007
Read Lead exposure and cardiovascular disease--a systematic review. by Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc1849948.txt.
Introduction
Navas-Acien and colleagues reviewed in 2007 the evidence tying lead exposure to cardiovascular disease in people. Lead is a toxic metal once common in paint and gasoline. Its effect on blood pressure was suspected, but the wider heart evidence had not been drawn together.
The team gathered all observational studies on lead and heart outcomes. Many studies, including ones that followed people over time and ones in uniform social groups, found higher blood pressure with higher lead exposure. Several showed a dose-response pattern, where more lead meant higher pressure. Lab models confirmed the blood pressure effect. Studies also linked lead to deaths from heart disease and stroke and to peripheral arterial disease, sometimes below five micrograms per deciliter of blood. They judge the hypertension evidence sufficient for a causal claim, the rest suggestive.
Catalog record
| CREATOR | Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. |
|---|---|
| YEAR | 2007 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC0 1.0 Universal |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Lead Exposure and Cardiovascular Disease—A Systematic Review By Ana Navas-Acien, Eliseo Guallar, Ellen K Silbergeld, Stephen J Rothenberg Published in: Environmental Health Perspectives DOI: 10.1289/ehp.9785 ABSTRACT Abstract Objective This systematic review evaluates the evidence on the association between lead exposure and cardiovascular end points in human populations. Methods We reviewed all observational studies from database searches and citations regarding lead and cardiovascular end points. Results A positive association of lead exposure with blood pressure has been identified in numerous studies in different settings, including prospective studies and in relatively homogeneous socioeconomic status groups. Several studies have identified a dose–response relationship. Although the magnitude of this association is modest, it may be underestimated by measurement error. The hypertensive effects of lead have been confirmed in experimental models. Beyond hypertension, studies in general populations have identified a positive association of lead exposure with clinical cardiovascular outcomes (cardiovascular, coronary heart disease, and stroke mortality; and peripheral arterial disease), but the number of studies is small. In some studies these associations were observed at blood lead levels < 5 μg/dL. Conclusions We conclude that the evidence is sufficient to infer a causal relationship of lead exposure with hypertension. We conclude that the evidence is suggestive but not sufficient to infer a causal relationship of lead exposure with clinical cardiovascular outcomes. There is also suggestive but insufficient evidence to infer a causal relationship of lead exposure with heart rate variability. Public Health Implications These findings have immediate public health implications. Current occupational safety standards for blood lead must be lowered and a criterion for screening elevated lead exposure needs to be established in adults. Risk assessment and economic analyses of lead exposure impact must include the cardiovascular effects of lead. Finally, regulatory and public health interventions must be developed and implemented to further prevent and reduce lead exposure. Keywords: atherosclerosis, blood pressure, cardiovascular disease, heart rate variability, hypertension, lead, systematic review BACKGROUND Cardiovascular disease is the leading cause of mortality and a primary contributor to the burden of disease worldwide (Lopez et al. 2006). Environmental toxicants, including lead and other metals, are potentially preventable exposures that may explain population variation in cardiovascular disease rates (Bhatnagar 2006; Weinhold 2004). However, after more than 100 years since initial reports suggested a link between lead exposure and cardiovascular outcomes (Lancéreaux 1881; Lorimer 1886), the contribution of lead to cardiovascular disease is still incompletely understood. Population research on the cardiovascular effects of lead has focused largely on the association with blood pressure and hypertension. Several reviews and metaanalyses combining data from more than 30 original studies and around 60,000 participants have examined the evidence relating blood lead to blood pressure or hypertension [Hertz-Picciotto and Croft 1993; Nawrot et al. 2002; Schwartz 1995; Sharp et al. 1987; Staessen et al. 1994, 1995; U.S. Environmental Protection Agency (U.S. EPA) 2006]. All these reviews concluded that there was a positive association between blood lead levels and blood pressure (Table 1). The estimated increase in systolic blood pressure associated with a 2-fold increase in blood lead levels (e.g., from 5 to 10 μg/dL) ranged across reviews from 0.6 to 1.25 mmHg. This epidemiologic relationship is also supported by a large body of experimental and mechanistic evidence (U.S. EPA 2006). Because lead exposure is widespread, even a modest effect would imply that lead exposure is an important determinant of blood pressure levels and hypertension in human populations. [Table: Reviews of the association between blood lead levels and blood pressure.] The cardiovascular effects of lead, however, are not limited to increased blood pressure and hypertension. Lead exposure has also been associated with an increased incidence of clinical cardiovascular end points such as coronary heart disease, stroke, and peripheral arterial disease (Lustberg and Silbergeld 2002; Menke et al. 2006; Navas-Acien et al. 2004; Schober et al. 2006), and with other cardiovascular function abnormalities such as left ventricular hypertrophy and alterations in cardiac rhythm (Cheng et al. 1998; Schwartz 1991). In the present article, our objective was to perform a systematic review of the epidemiologic evidence on the association of lead exposure with cardiovascular disease end points. Because previous reviews have examined the connection between lead and blood pressure in depth (Table 1), our systematic review emphasizes other clinical and intermediate cardiovascular outcomes to obtain a broader picture of the impact of lead on cardiovascular disease. Finally, we assessed the causal role of lead on blood pressure and cardiovascular disease by applying the criteria and terminology of the 2004 Surgeon General Report The Health Consequences of Smoking [U.S. Department of Health and Human Services (U.S. DHHS) 2004] to the available information. METHODS Search strategy and data abstraction We aimed to identify all observational studies assessing the association between lead exposure and cardiovascular end points. Using free text and key words (Appendix A), we searched PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed), EMBASE (http://www.embase.com/), and TOXLINE (http://toxnet.nlm.nih.gov/) through August 2006 with no language restrictions. In addition we manually reviewed the reference lists from relevant original research and review articles and documents. For lead exposure, we included studies that used biomarkers (lead levels in blood, bone, or other specimens), environmental measures (airborne lead levels), or indirect measures (job titles, job exposure matrices, living in lead-contaminated areas). For cardiovascular end points, we included studies that reported clinical cardiovascular end points (cardiovascular disease, coronary heart disease, stroke, or peripheral arterial disease) and intermediate cardiovascular end points (left ventricular mass, heart rate, heart rate variability, or electrocardiographic abnormalities) other than blood pressure levels or hypertension. We excluded publications containing no original research, studies not carried out in humans, case reports, case series, ecologic studies, studies lacking a cardiovascular outcome, and studies lacking data on lead exposure (Figure 1). For studies with multiple publications on the same population, we selected the publication with the longest follow-up. For studies with equivalent follow-up periods, we selected the study with the largest number of cases or the most recent publication. We excluded autopsy studies measuring lead in arterial tissue and studies based on polycardiography and ballistocardiograpy, techniques no longer in use. For consistency, blood lead levels were converted to micrograms per deciliter. [Figure: Flow diagram of study selection process. Databases: PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed); EMBASE (http://www.embase.com/); TOXLINE (http://toxnet.nlm.nih.gov/).] We adapted the criteria used by Longnecker et al. (1988) to assess study quality for studies of clinical end points and the criteria used by Appel et al. (2002) to assess study quality for studies of intermediate end points (Appendices B and C). Statistical methods Measures of association (odds ratios, prevalence ratios, standardized mortality ratios, relative risks, relative hazards, comparisons of means, linear regression coefficients, correlation coefficients) and their standard errors were abstracted or derived from published data (Greenland 1987). For studies reporting measures of association for population subgroups (Cooper et al. 1985; Malcolm 1971), we pooled the measures of association using an inverse-variance weighted random-effects model (Egger et al. 2001). Because of substantial heterogeneity and methodologic limitations of the original studies, we considered that quantitative pooling was inappropriate. We thus present a qualitative systematic review of the available evidence. RESULTS Lead and clinical cardiovascular disease in general populations Twelve studies met our inclusion criteria (Table 2). Lead was measured in blood in all the prospective cohort studies (Kromhout 1988; Lustberg and Silbergeld 2002; Menke